Canada: Closer Than They Appear: Federal Court Of Appeal Considers Definition Of "Innovative Drug"

A recent decision of the Federal Court of Appeal provides some further guidance as to when a drug will be considered an "innovative drug" and able to enjoy the benefit of data protection. In our October 2012 Blakes Bulletin on Life Sciences: I Want a New Drug: Developments in Data Protection for Innovative Drugs, we highlighted two decisions of the Federal Court that considered the scope and application of the data protection regime for innovative drugs in Canada.

In Takeda Canada Inc. v. The Minister of Health, the Federal Court of Appeal (FCA), in a split decision, upheld the prior decisions of the Federal Court of Canada (FCC) and the Minister of Health (Minister) to refuse to list Takeda's drug DEXILANT on the Register of Innovative Drugs (Register).

Decisions of the Minister and the FCC

A manufacturer of a new drug is required to submit detailed safety and efficacy information to the Minister as part of its New Drug Submission (NDS) in order to receive approval to market and sell the drug in Canada. Where the drug in question is an "innovative drug", the data protection provisions in the Food and Drug Regulations (Regulations) prevent, for a period of time, applications for generic drugs from relying on the data that was submitted in support of the NDS for the innovative drug. Innovative drugs that qualify for data protection are listed on the Register.

An "innovative drug" is defined in the Regulations as "a drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph" (emphasis added).

Takeda requested that the Minister list its drug DEXILANT on the Register to indicate that it was eligible for data protection. The Minister rejected Takeda's request for data protection on the ground that DEXILANT's medicinal ingredient, dexlansoprazole, is an enantiomer of lansoprazole, a previously approved medicinal ingredient and, therefore, DEXILANT did not meet the definition of an innovative drug.

Takeda brought an application in the FCC for judicial review of the Minister's decision to deny data protection. Takeda argued that the Minister's interpretation of the definition of "innovative drug" in the Regulations was overly restrictive and that enantiomers should not be excluded merely because they are listed in the definition as examples of drugs that are mere variations of previously approved drugs. Takeda submitted that the Minister should also have considered the nature and extent of the data submitted by Takeda in support of the NDS.

Based on the principles of statutory interpretation, the FCC found that the definition of "innovative drug" in the Regulations, when read in its grammatical and ordinary sense, was relatively clear. The Court found that, based on the ordinary meaning of the word "variation", it was reasonable that an enantiomer, along with the other listed examples, will always be a mere "variation" and therefore not an innovative drug. Although the Minister may make additional inquiries (including with respect to the nature and extent of the data submitted in an NDS) to determine whether a medicinal ingredient that is not one of the types listed in the definition may nonetheless be a mere variation, the Court found that medicinal ingredients that are listed are excluded from the outset and further consideration is not required.

Furthermore, the Court also considered that this interpretation was consistent with Canada's international treaty obligations, which were the underlying reason for the implementation of the data protection provisions in the first place. These treaty obligations apply to the protection of "new chemical entities" rather than all "new drugs". Therefore, the mere fact that extensive data may be required to support an NDS will not automatically make the medicinal ingredient an "innovative drug".

The FCC dismissed Takeda's appeal of the decision of the Minister on these grounds.

Federal Court of Appeal

Takeda made a further appeal to the FCA, which denied its appeal by a two-to-one split. The majority of the FCA framed the issue before it as one of statutory interpretation. The FCA agreed with the FCC that the applicable standard of review was that of correctness, namely, was the definition of "innovative drug", taken in context and with attention given to its text and purpose, interpreted correctly by both the Minister and the FCC?

The majority sided with the Minister and found that the FCC had made no error in its decision, agreed that the listed examples in the definition of "innovative drug" are variations, and dismissed the appeal.

The majority also noted that the decision as to whether an enantiomer was sufficiently different as to be considered an "innovative drug" was a policy decision made when crafting the Regulations, and bearing in mind Canada's international treaty obligations. If a party feels that the Regulations are not all-inclusive, it is a matter for the Canadian government to remedy through the legislative process. Courts should not thwart the policy decision behind the definition of "innovative drug", especially where the wording of the provision was, in the minds of the majority, sufficiently precise.

In a very strong dissent, Justice Stratas disagreed and held that DEXILANT could be considered eligible for data protection and proposed that the matter be remitted to the Minister for reconsideration. In his dissenting reasons, Justice Stratas rejected a literal reading of the definition of "innovative drug" in the Regulations and adopted the purposive construction supported by Takeda.

Specifically, Justice Stratas reasoned that the substances listed as "variations" under the definition of "innovative drug" were examples of the types of substances that would normally be regarded as variations. He expressed the view that the controlling idea in the definition was whether or not a medicinal ingredient is really a "variation", and not whether the medicinal ingredient fell within the listed examples. Justice Stratas found that "variation" does not have a specific scientific meaning and that the evidence supported a conclusion that some enantiomers are quite different.

Further, Justice Stratas noted that the level of testing required to establish the safety and efficacy of a drug is relevant to a consideration of whether it should be entitled to data protection. For example, the drug submission requirements related to safety and efficacy for some enantiomers are the same as those for any new active substance. These considerations were found to be consistent with the relevant provisions of the international treaties which shape Canada's data protection regime.

Justice Stratas rejected a strict and literal interpretation of the definition because it would lead to results which are contrary to the purpose of the Regulations, as well as Canada's international treaty obligations. He found that the proper interpretation of the term "innovative drug" under the Regulations can include a drug such as DEXILANT.

As with the earlier decisions related to the drugs ELOXATIN and THALOMID, whether a drug is an "innovative drug" under the Regulations is not necessarily a straightforward analysis. In this case, even the FCA was divided as to whether the drug at issue qualified for data protection.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Oct 2016, Seminar, Toronto, Canada

Please join members of the Blakes Commercial Real Estate group as they discuss five key provisions of a commercial real estate purchase agreement that are often the subject of much negotiation but are sometimes misunderstood.

1 Nov 2016, Seminar, Toronto, Canada

What is the emotional culture of your organization?

Every organization and workplace has an emotional culture that can have an impact on everything from employee performance to customer or client satisfaction.

3 Nov 2016, Seminar, Toronto, Canada

Join leading lawyers from the Blakes Pensions, Benefits & Executive Compensation group as they discuss recent updates and legal developments in pension and employee benefits law as well as strategies to identify and minimize common risks.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.